167 related articles for article (PubMed ID: 36270849)
21. Low-grade oncocytic renal tumor (LOT): mutations in mTOR pathway genes and low expression of FOXI1.
Morini A; Drossart T; Timsit MO; Sibony M; Vasiliu V; Gimenez-Roqueplo AP; Favier J; Badoual C; Mejean A; Burnichon N; Verkarre V
Mod Pathol; 2022 Mar; 35(3):352-360. PubMed ID: 34531523
[TBL] [Abstract][Full Text] [Related]
22. TSC/mTOR Pathway Mutation Associated Eosinophilic/Oncocytic Renal Neoplasms: A Heterogeneous Group of Tumors with Distinct Morphology, Immunohistochemical Profile, and Similar Genetic Background.
Pivovarcikova K; Alaghehbandan R; Vanecek T; Ohashi R; Pitra T; Hes O
Biomedicines; 2022 Jan; 10(2):. PubMed ID: 35203531
[TBL] [Abstract][Full Text] [Related]
23. Low-grade oncocytic tumor (LOT) - a new renal entity ready for a prime time: An updated review.
Mansoor M; Siadat F; Trpkov K
Histol Histopathol; 2022 May; 37(5):405-413. PubMed ID: 35156688
[TBL] [Abstract][Full Text] [Related]
24. Renal cell tumour characteristics in patients with the Birt-Hogg-Dubé cancer susceptibility syndrome: a retrospective, multicentre study.
Benusiglio PR; Giraud S; Deveaux S; Méjean A; Correas JM; Joly D; Timsit MO; Ferlicot S; Verkarre V; Abadie C; Chauveau D; Leroux D; Avril MF; Cordier JF; Richard S;
Orphanet J Rare Dis; 2014 Oct; 9():163. PubMed ID: 25519458
[TBL] [Abstract][Full Text] [Related]
25. p63 immunohistochemistry differentiates salivary gland oncocytoma and oncocytic carcinoma from metastatic renal cell carcinoma.
McHugh JB; Hoschar AP; Dvorakova M; Parwani AV; Barnes EL; Seethala RR
Head Neck Pathol; 2007 Dec; 1(2):123-31. PubMed ID: 20614263
[TBL] [Abstract][Full Text] [Related]
26. Identification of clear cell renal cell carcinoma and oncocytoma using a three-gene promoter methylation panel.
Pires-Luís AS; Costa-Pinheiro P; Ferreira MJ; Antunes L; Lobo F; Oliveira J; Henrique R; Jerónimo C
J Transl Med; 2017 Jun; 15(1):149. PubMed ID: 28662726
[TBL] [Abstract][Full Text] [Related]
27. Claudin-7 and claudin-8: immunohistochemical markers for the differential diagnosis of chromophobe renal cell carcinoma and renal oncocytoma.
Osunkoya AO; Cohen C; Lawson D; Picken MM; Amin MB; Young AN
Hum Pathol; 2009 Feb; 40(2):206-10. PubMed ID: 18799195
[TBL] [Abstract][Full Text] [Related]
28. Renal oncocytosis: a clinicopathological and cytogenetic study of 42 tumours occurring in 11 patients.
Giunchi F; Fiorentino M; Vagnoni V; Capizzi E; Bertolo R; Porpiglia F; Vatrano S; Tamberi S; Schiavina R; Papotti M; Bollito E
Pathology; 2016 Jan; 48(1):41-6. PubMed ID: 27020208
[TBL] [Abstract][Full Text] [Related]
29. Identification and Validation of Radiographic Enhancement for Reliable Differentiation of CD117(+) Benign Renal Oncocytoma and Chromophobe Renal Cell Carcinoma.
Amin J; Xu B; Badkhshan S; Creighton TT; Abbotoy D; Murekeyisoni C; Attwood KM; Schwaab T; Hendler C; Petroziello M; Roche CL; Kauffman EC
Clin Cancer Res; 2018 Aug; 24(16):3898-3907. PubMed ID: 29752278
[No Abstract] [Full Text] [Related]
30. Distinguishing Benign Renal Tumors with an Oncocytic Gene Expression (ONEX) Classifier.
McGillivray PD; Ueno D; Pooli A; Mendhiratta N; Syed JS; Nguyen KA; Schulam PG; Humphrey PA; Adeniran AJ; Boutros PC; Shuch B
Eur Urol; 2021 Jan; 79(1):107-111. PubMed ID: 32972793
[TBL] [Abstract][Full Text] [Related]
31. Morphological and Molecular Study of Hybrid Oncocytic/Chromophobe Tumor of the Kidney Associated with Sporadic Renal Oncocytosis and Chronic B-Cell Lymphocytic Leukemia: The Possible Contribution of Lymphoma to Renal Oncocytosis.
Idoate MA; Trigo I; Saenz de Zaitigui J; Pérez-Pérez M; Ríos JJ
Pathobiology; 2021; 88(4):313-322. PubMed ID: 33882490
[TBL] [Abstract][Full Text] [Related]
32. LMP2, a novel immunohistochemical marker to distinguish renal oncocytoma from the eosinophilic variant of chromophobe renal cell carcinoma.
Zheng G; Chaux A; Sharma R; Netto G; Caturegli P
Exp Mol Pathol; 2013 Feb; 94(1):29-32. PubMed ID: 22705098
[TBL] [Abstract][Full Text] [Related]
33. Claudin-7 immunohistochemistry in renal tumors: a candidate marker for chromophobe renal cell carcinoma identified by gene expression profiling.
Hornsby CD; Cohen C; Amin MB; Picken MM; Lawson D; Yin-Goen Q; Young AN
Arch Pathol Lab Med; 2007 Oct; 131(10):1541-6. PubMed ID: 17922590
[TBL] [Abstract][Full Text] [Related]
34. Immunohistochemical application of S100A1 in renal oncocytoma, oncocytic papillary renal cell carcinoma, and two variants of chromophobe renal cell carcinoma.
Kuroda N; Kanomata N; Yamaguchi T; Imamura Y; Ohe C; Sakaida N; Hes O; Michal M; Shuin T; Lee GH
Med Mol Morphol; 2011 Jun; 44(2):111-5. PubMed ID: 21717314
[TBL] [Abstract][Full Text] [Related]
35. Co-existence of ESC-RCC, EVT, and LOT as synchronous and metachronous tumors in six patients with multifocal neoplasia but without clinical features of tuberous sclerosis complex.
Lerma LA; Schade GR; Tretiakova MS
Hum Pathol; 2021 Oct; 116():1-11. PubMed ID: 34153307
[TBL] [Abstract][Full Text] [Related]
36. Eosinophilic Renal Cell Tumors With a TSC and MTOR Gene Mutations Are Morphologically and Immunohistochemically Heterogenous: Clinicopathologic and Molecular Study.
Tjota M; Chen H; Parilla M; Wanjari P; Segal J; Antic T
Am J Surg Pathol; 2020 Jul; 44(7):943-954. PubMed ID: 32091432
[TBL] [Abstract][Full Text] [Related]
37. Morphological, immunohistochemical, and chromosomal analysis of multicystic chromophobe renal cell carcinoma, an architecturally unusual challenging variant.
Foix MP; Dunatov A; Martinek P; Mundó EC; Suster S; Sperga M; Lopez JI; Ulamec M; Bulimbasic S; Montiel DP; Alaghehbandan R; Peckova K; Pivovarcikova K; Ondrej D; Rotterova P; Skenderi F; Prochazkova K; Dusek M; Hora M; Michal M; Hes O
Virchows Arch; 2016 Dec; 469(6):669-678. PubMed ID: 27631338
[TBL] [Abstract][Full Text] [Related]
38. Papillary renal cell carcinoma with cytologic and molecular genetic features overlapping with renal oncocytoma: Analysis of 10 cases.
Michalova K; Steiner P; Alaghehbandan R; Trpkov K; Martinek P; Grossmann P; Montiel DP; Sperga M; Straka L; Prochazkova K; Cempirkova D; Horava V; Bulimbasic S; Pivovarcikova K; Daum O; Ondic O; Rotterova P; Michal M; Hora M; Hes O
Ann Diagn Pathol; 2018 Aug; 35():1-6. PubMed ID: 30072012
[TBL] [Abstract][Full Text] [Related]
39. TSC/MTOR -associated Eosinophilic Renal Tumors Exhibit a Heterogeneous Clinicopathologic Spectrum : A Targeted Next-generation Sequencing and Gene Expression Profiling Study.
Xia QY; Wang XT; Zhao M; He HY; Fang R; Ye SB; Li R; Wang X; Zhang RS; Lu ZF; Ma HH; Wang ZY; Rao Q
Am J Surg Pathol; 2022 Nov; 46(11):1562-1576. PubMed ID: 35980750
[TBL] [Abstract][Full Text] [Related]
40. Low-grade oncocytic tumor of kidney harboring TSC/MTOR mutation: clinicopathologic, immunohistochemical and molecular characteristics support a distinct entity.
Zhang HZ; Xia QY; Wang SY; Shi MJ; Wang SY
Virchows Arch; 2022 May; 480(5):999-1008. PubMed ID: 35099634
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
